CLOs on the Move

Otsuka America

www.otsuka-us.com

 
There are three Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis. Otsuka Maryland Medicinal Laboratories, Inc. (OMML) is a basic research center investigating pharmacological compounds.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Katheryn Eisenmann
Senior Director, Corporate Counsel Profile
Maureen Nagelberg
Associate Compliance Officer Profile
Ashlee Hamilton
Associate Director, Corporate Counsel, Brand Regulatory Profile
Fred Freeman
Director, Corporate Counsel Profile
Nicole Park
Director, Corporate Counsel (Regulatory/IP) Profile

Jobs

Similar Companies

Beckman Coulter

Beckman Coulter Inc. is a Danaher Corporation company that develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing.

Neotropix

Neotropix is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vascular Technology

Vascular Technology Incorporated is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TechLab

TechLab is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.